Background
==========

Cardiac natriuretic peptides, atrial and brain natriuretic peptides (ANP and BNP, respectively) are known to have anti-cardiac hypertrophy effects. ANP and BNP bind to their common receptor, guanylyl cyclase-A, which subsequently activates cGMP-protein kinase G (PKG) pathway. Precise molecular mechanisms by which cardiac natriuretic peptides protect hearts against pathological cardiac hypertrophy still remain unclear, however. Transient receptor potential (TRP) C6, an ion channel responsible for the receptor-activated Ca2+ entry, has been shown to be a positive regulator of calcineurin-NFAT signaling pathway that drives pathologic cardiac remodeling \[[@B1]\]. In this study to elucidate the molecular pathways, by which cardiac natriuretic peptides negatively regulate pro-hypertrophic signaling, we investigated effects of ANP on TRPC6-calcineurin-NFAT signaling.

Results
=======

In rat neonatal ventricular myocytes (NRVM), ANP significantly inhibited ET-1-induced Ca2+ entry and NFAT activation. The inhibitory effect of ANP on ET-1-induced Ca entry was abolished in the presence of BTP2, a TRPC inhibitor. In HEK293 cells expressing TRPC6, ANP dramatically inhibited TRPC6-mediated Ca2+ entry and cationic currents. The inhibitory effect of ANP on TRPC6 was abolished in the presence of specific PKG inhibitors or by the substitution of alanine for threonine at 69^th^amino acid of TRPC6, which has been shown to be phosphorylated by PKG.

Conclusion
==========

All these results suggest that inhibition of TRPC6 is an important component, by which cardiac natriuretic peptides-GC-A-cGMP-PKG signaling pathway protects the hearts from pathological cardiac remodeling.
